⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VTRS News
Viatris Inc. Common Stock
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036
globenewswire.com
ABBV
ALC
APLS
BHC
JNJ
PFE
REGN
TEVA
VTRS
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
globenewswire.com
IRD
VTRS
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
prnewswire.com
VTRS
Intelligent Building Automation Technologies Market worth $191.14 billion by 2030 | MarketsandMarkets™
prnewswire.com
HON
JCI
ETN
TT
CARR
ROK
EMR
LRCX
SD
AVY
CTAS
CL
CLVT
CPB
CVS
DHR
DE
DOV
DTE
ECL
ED
EFX
EMN
EXC
FAST
FDX
FIS
FTV
GD
GE
GPC
GWW
HII
HPE
IBM
ITW
IVZ
J
JLL
L
LNT
LUV
LYB
M
MAS
MDT
MMC
MNST
MSFT
MTCH
MU
NDAQ
NEE
NI
NOC
NOW
NTRS
NVDA
NWSA
OMC
ORLY
OTIS
PCAR
PAYX
PEP
PFE
PG
PGR
PH
PLD
PM
PNW
PPG
PPL
PRGO
PSA
QCOM
RCL
RF
RHI
RIVN
RL
ROST
RS
SBUX
SCL
SDRL
SEE
SIRI
SNA
SNPS
SO
SPG
STX
SWK
SYK
SYY
T
TFX
TGT
TMO
TOL
TOP
TRMB
TSLA
TTWO
TXN
TXT
TYL
UDR
ULTA
UNH
UNM
UPS
URI
VRSN
VRTX
VTR
VTRS
VZ
WDC
WEC
WFC
WHR
WMB
WST
XOM
XRAY
XYL
YUM
ZBRA
ZION
ZTS
Boehringer Ingelheim Granted Emergency Use Authorization for New World Screwworm Treatments in Dogs and Cats
prnewswire.com
VTRS
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
globenewswire.com
VTRS
Antigen Carriage Associated with Lamotrigine-Induced DRESS
prnewswire.com
VTRS
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
globenewswire.com
VTRS
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
prnewswire.com
VTRS
Prescription Weight Loss Medications Market Projected to Reach US$ 40.13 Billion by 2035, Supported by Clinical Adoption and Pipeline Expansion Says Astute Analytica
globenewswire.com
LLY
NVO
AMGN
VTRS
ZTS
REGN